Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service decompression & minimally invasive spine cases in Hawaii: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (250 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 247 | 53% |
| 2020 | 7 | 256 | 55% |
| 2021 | 8 | 275 | 57% |
Laminotomy, laminectomy, interspinous devices; the MIS call point. Professional codes (what the surgeon bills): CPT 63030, 63047, 63020, 63045, 22867; the hospital bills MS-DRG 518, 519, 520.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Hawaii; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 219 | 9,586−3.4%/yr | −3.4%/yr | 2.8 | 7% | 10,100 in 2030+0.8%/yr |
| Arizona | 72 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 4 | 124−3.3%/yr | −3.3%/yr | 0.90.3× | 36% | 150 in 2030+3%/yr |
Decompression & minimally invasive spine in every state, and its device makers · Every procedure market in Hawaii · Every state · Compare with California
| 2024 |
| 234 |
| 62% |
| 2025 est. | ≈ 130 | – |
| 2026 est. | ≈ 130 | – |
| 2022 | 8 | 250 | 59% |
| 2023 | 7 | 227 | 61% |
| 2024 | 7 | 234 | 62% |
| 2025 from claims | – | 130 105–153 | 62% |
| 2026 forecast | – | 132 104–166 | 61% |
| 2027 forecast | – | 134 99–177 | 62% |
| 2028 forecast | – | 135 96–187 | 62% |
| 2029 forecast | – | 137 93–196 | 62% |
| 2030 forecast | – | 138 91–205 | 62% |
In 2025, 49% inpatient hospital, 39% hospital outpatient, 12% surgery center. The share outside the hospital has moved +13 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 2,815−4.4%/yr |
| −4.4%/yr |
| 3.7 |
| 14% |
| 3,290 in 2030+2.6%/yr |
| Washington | 74 | 2,603−5.2%/yr | −5.2%/yr | 3.3 | 17% | 2,650 in 2030+0.3%/yr |
| Colorado | 51 | 2,105−5.5%/yr | −5.5%/yr | 4.2 | 5% | 2,480 in 2030+2.7%/yr |
| Oregon | 37 | 1,683−5.9%/yr | −5.9%/yr | 3.9 | 38% | 1,690 in 20300%/yr |
| Utah | 31 | 1,279−3.9%/yr | −3.9%/yr | 5.6 | 16% | 1,510 in 2030+2.8%/yr |
| Nevada | 27 | 1,021−8%/yr | −8%/yr | 3.4 | 4% | 1,050 in 2030+0.5%/yr |
| Idaho | 23 | 876−1.5%/yr | −1.5%/yr | 4.2 | 1% | 1,130 in 2030+4.3%/yr |
| Montana | 11 | 616−3.5%/yr | −3.5%/yr | 3.2 | 9% | 590 in 2030−0.8%/yr |
| Alaska | 10 | 340+0.8%/yr | +0.8%/yr | 2.8 | 13% | 430 in 2030+3.8%/yr |
| Wyoming | 9 | 331−4.1%/yr | −4.1%/yr | 3.0 | 10% | 310 in 2030−0.8%/yr |
| New Mexico | 7 | 250−13%/yr | −13%/yr | 1.0 | 0% | 350 in 2030+5.7%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Globus Medical leads with 77% of company spending on these surgeons in 2025, +69 pts on 2024.
In 2025, 3 companies reported engagement with Hawaii’s surgeons worth $17K in consulting, speaking, meals and travel tied to these products, about $2,485 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.